UCB’s bimekizumab granted marketing authorisation by MHRA for plaque psoriasis

pharmafile | August 27, 2021 | News story | Medical Communications  

UCB’s bimekizumab has been granted marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA)  for the treatment of adults with moderate to severe plaque psoriasis.

This authorisation from the MHRA makes it one of the first treatments to receive marketing authorisation through the new post-Brexit licensing pathway.

Bimekizumab is the first treatment authorised by the MHRA to selectively inhibit both IL-17A and IL-17F for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

NICE recommended bimekizumab for the treatment of adults with severe plaque psoriasis on 2 August 2021.

Claire Brading, Managing Director UK & Ireland, UCB, said: “We are pleased to have received marketing authorisation for bimekizumab from the MHRA and look forward to making this new treatment option available to patients in England, Scotland and Wales.

“We have witnessed first-hand the mental strength and resilience needed to live with this condition. Our belief is that success comes from putting people living with health conditions at the very heart of medicines development, from discovery, through R&D, to marketing authorisation and beyond.”

Professor Richard Warren, Consultant Dermatologist, Salford Royal NHS Foundation Trust, said: “Psoriasis impacts every part of the lives of people living with the condition, from work to relationships.

“Bimekizumab has shown strong results in head-to-head trials with higher rates of skin clearance achieved versus some of the most prescribed therapies, a key outcome for patients.

 “It is fantastic to see bimekizumab receive marketing authorisation from the MHRA, offering a highly effective option for patients suffering from moderate to severe plaque psoriasis.”

 Lilly Subbotin

Related Content

No items found

Latest content